{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saquinavir%2Fritonavir&page=2", "query": { "intervention": "Saquinavir/ritonavir", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 46, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saquinavir%2Fritonavir&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saquinavir%2Fritonavir&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T18:10:51.554Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00084058", "title": "Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 26, "start_date": null, "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084058" }, { "nct_id": "NCT00038532", "title": "Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Amprenavir/ritonavir", "type": "DRUG" }, { "name": "Saquinavir/ritonavir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-04-01", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038532" }, { "nct_id": "NCT00035932", "title": "Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir + ritonavir + tenofovir + nucleoside", "type": "DRUG" }, { "name": "Atazanavir + saquinavir + tenofovir + nucleoside", "type": "DRUG" }, { "name": "Lopinavir/ritonavir + tenofovir + nucleoside", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 571, "start_date": "2001-11", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2010-12-24", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 29, "location_summary": "San Francisco, California • Torrance, California • Boulder, Colorado + 23 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035932" }, { "nct_id": "NCT00000920", "title": "Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Pregnancy" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 24, "start_date": null, "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 14, "location_summary": "Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000920" }, { "nct_id": "NCT00000918", "title": "A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": "2002-02", "has_results": false, "last_update_posted_date": "2012-05-21", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Menlo Park", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000918" }, { "nct_id": "NCT00000913", "title": "A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "3 Years to 16 Years" }, "enrollment_count": 50, "start_date": null, "completion_date": "2001-04", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000913" }, { "nct_id": "NCT00039741", "title": "Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)", "type": "DRUG" }, { "name": "NNRTIs (EFV, NVP)", "type": "DRUG" }, { "name": "PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": "18 Years", "sex": "ALL", "summary": "30 Days to 18 Years" }, "enrollment_count": 266, "start_date": "2002-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 29, "location_summary": "Alhambra, California • Long Beach, California • Los Angeles, California + 22 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039741" }, { "nct_id": "NCT00000891", "title": "Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Delavirdine mesylate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 34, "start_date": null, "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 3, "location_summary": "Denver, Colorado • Chicago, Illinois • Cleveland, Ohio", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000891" }, { "nct_id": "NCT02556268", "title": "Interaction With HIV Antiretroviral Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-DDI" ], "interventions": [ { "name": "Riociguat (Adempas, BAY 63-2521)", "type": "DRUG" }, { "name": "ATRIPLA", "type": "DRUG" }, { "name": "COMPLERA", "type": "DRUG" }, { "name": "STRIBILD", "type": "DRUG" }, { "name": "TRIUMEQ", "type": "DRUG" }, { "name": "Antiretroviral protease inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2016-02-23", "completion_date": "2016-12-07", "has_results": false, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 2, "location_summary": "Orlando, Florida • Boston, Massachusetts", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556268" }, { "nct_id": "NCT01252940", "title": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/RPV/TDF", "type": "DRUG" }, { "name": "PI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 482, "start_date": "2010-11", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-10-03T18:10:51.554Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252940" } ] }